WO2005063260A3 - Methods and compositions for the prevention of toxic side effects of aminoglycoside medications - Google Patents

Methods and compositions for the prevention of toxic side effects of aminoglycoside medications Download PDF

Info

Publication number
WO2005063260A3
WO2005063260A3 PCT/US2004/043124 US2004043124W WO2005063260A3 WO 2005063260 A3 WO2005063260 A3 WO 2005063260A3 US 2004043124 W US2004043124 W US 2004043124W WO 2005063260 A3 WO2005063260 A3 WO 2005063260A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
aminoglycoside
medications
prevention
Prior art date
Application number
PCT/US2004/043124
Other languages
French (fr)
Other versions
WO2005063260A2 (en
Inventor
Peter S Steyger
Sigrid Myrdal
Original Assignee
Univ Oregon Health & Science
Peter S Steyger
Sigrid Myrdal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science, Peter S Steyger, Sigrid Myrdal filed Critical Univ Oregon Health & Science
Publication of WO2005063260A2 publication Critical patent/WO2005063260A2/en
Publication of WO2005063260A3 publication Critical patent/WO2005063260A3/en
Priority to US11/473,300 priority Critical patent/US20070082858A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

Compositions and methods for reducing and/or preventing antibiotic-related damage to cells of the inner ear and the kidney are provided. Such compositions and methods reduce or prevent hearing loss and kidney damage resulting from use of antibiotics, such as aminoglycoside antibiotics. The composition also find use in reducing or preventing inner ear and kidney damage associated with anti-neoplastic agents, other therapeutic drugs, and environmental factors.
PCT/US2004/043124 2003-12-22 2004-12-21 Methods and compositions for the prevention of toxic side effects of aminoglycoside medications WO2005063260A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/473,300 US20070082858A1 (en) 2004-12-21 2006-06-21 Methods and compositions for the prevention of toxic side effects of aminoglycoside medications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53181203P 2003-12-22 2003-12-22
US60/531,812 2003-12-22

Publications (2)

Publication Number Publication Date
WO2005063260A2 WO2005063260A2 (en) 2005-07-14
WO2005063260A3 true WO2005063260A3 (en) 2005-10-13

Family

ID=34738706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/043124 WO2005063260A2 (en) 2003-12-22 2004-12-21 Methods and compositions for the prevention of toxic side effects of aminoglycoside medications

Country Status (1)

Country Link
WO (1) WO2005063260A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073855A1 (en) * 2005-12-23 2007-07-05 Bayer Healthcare Ag Use of adenosine a1 receptor agonists for the protection of renal cells against toxic effects caused by aminoglycosides during treatment of infectious diseases
WO2009023025A1 (en) * 2007-08-13 2009-02-19 Board Of Trustees Of Southern Illinois University Methods for treatment and prevention of ototoxicity by sirna

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037757A1 (en) * 1998-01-22 1999-07-29 Administrators Of The Tulane Educational Fund Cubilin protein, dna sequences encoding cubilin and uses thereof
WO2000018949A2 (en) * 1998-09-30 2000-04-06 University Of Utah Research Foundation Delivery of phosphoinositide polyphosphates into cells
WO2003080103A1 (en) * 2002-04-25 2003-10-02 Recepticon Aps Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037757A1 (en) * 1998-01-22 1999-07-29 Administrators Of The Tulane Educational Fund Cubilin protein, dna sequences encoding cubilin and uses thereof
WO2000018949A2 (en) * 1998-09-30 2000-04-06 University Of Utah Research Foundation Delivery of phosphoinositide polyphosphates into cells
WO2003080103A1 (en) * 2002-04-25 2003-10-02 Recepticon Aps Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KRAGH S ET AL: "EVIDENCE THAT EPITHELIAL GLYCOPROTEIN 330/MEGALIN MEDIATES UPTAKE OF POLYBASIC DRUGS", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 96, no. 3, September 1995 (1995-09-01), pages 1404 - 1413, XP009000656, ISSN: 0021-9738 *
SCHMITZ C ET AL: "Megalin deficiency offers protection from renal aminoglycoside accumulation", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 277, no. 1, 4 January 2002 (2002-01-04), pages 618 - 622, XP002221999, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2005063260A2 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
WO2006074051A3 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
WO2005025499A3 (en) Hydrophobic drug compositions containing reconstitution enhancer
EP1864665A4 (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2004108093A3 (en) Antiseptic compositions, methods and systems
WO2006124698A3 (en) Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
WO2007086001A3 (en) Novel pyridine derivatives
AU2001239725A1 (en) Antibacterial agents
TW200700406A (en) Novel thiophene derivatives
TW200716591A (en) Novel thiophene derivatives
AU2003273276A1 (en) Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
PL1792927T3 (en) Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient
TW200738670A (en) Novel thiophene derivatives
WO2007100776A3 (en) Antimicrobial compositions and methods for locking catheters
EP1594444A3 (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
AU2003901008A0 (en) Composition for the treatment and prevention of bacterial infections
WO2008142569A3 (en) Topical compositions containing magaldrate
WO2007059226A3 (en) Photoactivatable antimicrobial agents
WO2006034001A3 (en) Methods of treating hiv infection
WO2006121522A3 (en) Implantable sensors and pumps, anti-scarring agents, and therapeutic compositions
WO2006007671A3 (en) Therapeutically combinations
WO2005009460A3 (en) Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
CA2370003A1 (en) A composition and method for the enhancement of the efficacy of drugs
AU2003299561A1 (en) Compositions and methods for treating bacterial infections with protein-dalbavancin complexes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase